Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC.
J. D. Patel
Research Funding - Allos Therapeutics
C. G. Azzoli
Research Funding - Allos Therapeutics
G. A. Weems
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
A. Koutsoukos
Employment or Leadership Position - Allos Therapeutics
Stock Ownership - Allos Therapeutics
P. Zatloukal
No relevant relationships to disclose
K. Kelly
Consultant or Advisory Role - Allos Therapeutics